RxDoctor Payments Data

Eric Eichhorn, MD

Interventional Cardiology · Dallas, TXNPI 1972595510

Payments from drug & device makers

$14,047in general payments, 2019–2025

Across 585 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$2K
  • Amgen$1K
  • Pfizer$1K
  • Merck$905
  • Novartis$824
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$664
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$340%
  • Food & beverage$13,91999%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,047 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$153,691
Medicare patients
492
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat45$626,571
OpsumitMacitentan31$388,658
EliquisApixaban132$143,987
EntrestoSacubitril/Valsartan52$82,536
MultaqDronedarone Hcl42$68,718
Ambrisentan14$39,656
FarxigaDapagliflozin Propanediol23$32,937
Repatha SyringeEvolocumab30$32,346
Repatha SureclickEvolocumab30$27,039
XareltoRivaroxaban13$18,725
Praluent PenAlirocumab12$15,407
JardianceEmpagliflozin14$11,934
Metoprolol Succinate367$7,855
Milrinone Lactate30$6,524
Midodrine Hcl38$4,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$614$626,57145 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,562$388,65831 claims
PfizerEliquis$1,007$143,987132 claims
NovartisEntresto$824$82,53652 claims
Sanofi-aventis U.S. LLCMultaq$495$68,71842 claims
AstraZenecaFarxiga$314$32,93723 claims
Johnson & JohnsonXarelto$279$18,72513 claims
Boehringer IngelheimJardiance$194$11,93414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →